MARKET WIREStock Titan • 1d ago
72.7% of treated patients survived three years, versus 45.8% in historical comparisons.Stock Titan report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
Why OSTX Stock dropped -7.26% Today — RQD Quant Desk Flash
$1.15 -7.26% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.13
OS Therapies Incorporated (OSTX) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $59.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on OSTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is OSTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, OS Therapies Incorporated (NYSE: OSTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.15 (-7.26% 1D, market cap $59.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OSTX ranks #804 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does OSTX compare to APLM and SPRO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OSTX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APLM (Apollomics Inc. (Class A)) holds a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $60.4M) and SPRO (Spero Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E 7.5x, ROIC 26.6%, cap $60.6M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for OSTX?
▼
Per OSTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001795091), OS Therapies Incorporated generated $80.4M in revenue (+321.3% YoY), -$28.8M in net income, and -$14.2M in free cash flow against $6.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.13 (-1.50%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OSTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY OSTX SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.45-13.1% Next Q
38
Q2 (-2Q)Grade E$1.26-2.4% Next Q
35
Q3 (-1Q)Grade E$1.23-6.5% Next Q
33
CurrentGrade E$1.15-9.6% Hist 90D α
30
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a OSTX Turnaround Squeeze
While OSTX currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.56) and Max Pain ($1.21) forces dealer call-delta covering toward $2.36.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $OSTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OSTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why OSTX Stock dropped -7.26% Today — RQD Quant Desk Flash
OS Therapies Incorporated (OSTX) dropped -7.26% to $1.15, trading at 2% of its 52-week range ($1.15 – $2.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.15 – $2.25) with RSI-14 at 28.5 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.15 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live OSTX Headlines & Catalysts
RISK WATCHStocksToTrade • 1d ago
OSTX Stock Holds Tight Range As Traders Probe Weak FinancialsStocksToTrade report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
A 200,000-option award to OS Therapies (OSTX) medical chief Robert Petit has a $1.25 exercise price.Stock Titan report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREKalkine Media • 2d ago
OS Therapies Grants 200,000 Stock Options to CMO Robert PetitKalkine Media report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
CEO receives 900,000 options at OS Therapies (OSTX), vesting monthly subject to continued employment.Stock Titan report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
CFO receives 300,000 OS Therapies (OSTX) options with a $1.25 exercise price per share.Stock Titan report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
A director receives 300,000 OS Therapies (OSTX) options at $1.25, vesting monthly with continued service.Stock Titan report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
300,000 options at $1.25 go to OS Therapies (OSTX) commercial chief Kerry M. Clem.Stock Titan report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 15d ago
OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 MillionProceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestonesCompany expects to complete early market access regulatory a
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OSTX)
- ✓Walkthrough of OSTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OSTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.53%▼ SUPPORT BREAKDOWN
2026-11-04O $1.24H $1.24L $1.15C $1.15VOL 933.0K
RES: $1.83SUP: $1.17SMA50: $1.56SMA200: $1.56
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
OSTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +321.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on OSTX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for OSTX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OSTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OSTX)
Health Care Rank #804 of 1015
⚔️ APLM vs OSTX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (OSTX vs. APLM, SPRO, INCR, XBIT)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, OS Therapies Incorporated (OSTX) ranks #804 by composite RQD confidence (30/100, grade E) and #716 by equity capitalization ($59.8M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. APLM currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with OSTX at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OSTX
ACTIVE
OS Therapies Incorporated | E | 30/100 | — | — | -35.0% | -7.26% | $59.8M | Benchmark Subject |
| APLM Apollomics Inc. (Class A) | D+ | 55/100 | — | — | — | +0.73% | $60.4M | /aplm-vs-ostx → |
| SPRO Spero Therapeutics Inc. | D- | 40/100 | 7.5x | — | 26.6% | -1.89% | $60.6M | /spro-vs-ostx → |
| INCR Intercure Ltd. | D | 46/100 | — | — | — | +2.02% | $60.8M | /incr-vs-ostx → |
| XBIT XBiotech Inc. | E | 32/100 | — | — | -35.0% | +2.13% | $58.5M | /xbit-vs-ostx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001795091 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), OS Therapies Incorporated (OSTX) reported GAAP revenue of $80.4M (+321.3% vs. FY2024 revenue of $19.1M , and +561.0% cumulative change since FY2023) , GAAP net income of -$28.8M, operating cash flow of -$14.2M, and free cash flow of -$14.2M (-95.5% YoY). On the balance sheet, OSTX closed FY2025 with $6.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $80.4M | -$28.8M | -$14.2M | -$14.2M | $6.8M | — |
| FY2024 (FY) | 2024-12-31 | $19.1M | -$8.9M | -$7.3M | -$7.3M | $5.5M | — |
| FY2023 (FY) | 2023-12-31 | $12.2M | -$7.8M | -$3.0M | -$3.0M | — | — |
3. OSTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OSTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, OS Therapies Incorporated (NYSE: OSTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.15 (-7.26% 1D, market cap $59.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OSTX ranks #804 in composite RQD confidence.
How does OSTX compare to APLM and SPRO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OSTX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APLM (Apollomics Inc. (Class A)) holds a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $60.4M) and SPRO (Spero Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E 7.5x, ROIC 26.6%, cap $60.6M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OSTX?
Per OSTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001795091), OS Therapies Incorporated generated $80.4M in revenue (+321.3% YoY), -$28.8M in net income, and -$14.2M in free cash flow against $6.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OSTX trading relative to its 50-day, 200-day, and 52-week technical levels?
OSTX last traded at $1.15 (-7.26% on volume of 932,996 shares), positioning the stock -26.28% below its 50-day simple moving average ($1.56) and -26.28% below its 200-day simple moving average ($1.56). Across its 52-week range of $1.15 to $2.25, OSTX sits at the 0.0% percentile with a 14-day RSI of 28.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.01 to $1.29).
ROARABLE RATING BRIEF • RQD 30/100 (E)
✓ SEC XBRL & RQD VERIFIED
OSTX — OS Therapies Incorporated: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
OS Therapies Incorporated (OSTX) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.15 (-7.26% 1D, market capitalization $59.8M).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -21.07%.
- Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
— The sector is Health Care and the industry is Biotechnology: Pharmaceutical Preparations. The profile describes OS Therapies Incorporated as a NYSE-listed issuer. Products, customers, and revenue model are not described in the source data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), OS Therapies Incorporated (OSTX) reported $80.4M in annual revenue (up from $19.1M in FY2024, +321.3% YoY) and -$28.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($12.2M revenue, -$7.8M net income) through FY2025, OSTX scaled operating cash flow to -$14.2M and free cash flow to -$14.2M, backed by $6.8M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -21.07% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.15 – $2.25 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
There are no upstream or downstream dependencies, no listed sector correlations, and no proprietary signals. — for supplier, customer, or bottleneck mapping.
- Key Question #1: Can OSTX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $80.4M and free cash flow of -$14.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is OSTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
OSTX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for OS Therapies Incorporated (OSTX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stock Titan • 1d ago
72.7% of treated patients survived three years, versus 45.8% in historical comparisons. Stock Titan report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH StocksToTrade • 1d ago
OSTX Stock Holds Tight Range As Traders Probe Weak Financials StocksToTrade report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
A 200,000-option award to OS Therapies (OSTX) medical chief Robert Petit has a $1.25 exercise price. Stock Titan report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Kalkine Media • 2d ago
OS Therapies Grants 200,000 Stock Options to CMO Robert Petit Kalkine Media report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
CEO receives 900,000 options at OS Therapies (OSTX), vesting monthly subject to continued employment. Stock Titan report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
CFO receives 300,000 OS Therapies (OSTX) options with a $1.25 exercise price per share. Stock Titan report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
A director receives 300,000 OS Therapies (OSTX) options at $1.25, vesting monthly with continued service. Stock Titan report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
300,000 options at $1.25 go to OS Therapies (OSTX) commercial chief Kerry M. Clem. Stock Titan report covering OS Therapies Incorporated (OSTX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
OSTX Bull vs. Bear Conversation Board — What's Your Call at $1.15?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OSTX 🐻 33% BEARISH CONVICTION
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH
🎯 Target: $1.60 (+29.0%)
📌 Pinned Debate Institutional accumulation and options positioning score 11/20 in the RQD rating, and a reported 72.7% three-year survival figure appea
The street is overcomplicating OS Therapies Incorporated (OSTX). Institutional accumulation and options positioning score 11/20 in the RQD rating, and a reported 72.7% three-year survival figure appears in the news wire.. With an RQD score of 30/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.34.
VolSurface_Trader 🐂 BULL
Both sides have a point here — OSTX's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH
🎯 Target: $1.00 (-19.4%)
Spot @ $1.24 ROIC of -35%, FCF yield of -21.07%, and reported revenue of $0.0M with FY 2025 net loss of -$28.8M point to a weak cash engine.
I respect the product at OS Therapies Incorporated, but the stock at $1.24 is a different story. ROIC of -35%, FCF yield of -21.07%, and reported revenue of $0.0M with FY 2025 net loss of -$28.8M point to a weak cash engine.. FCF yield is -21.07% and RQD sits at 30/100 (E) — why pay up here when you can wait for next quarter's numbers?